An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response

American Journal of Gastroenterology

Volumn 103, Issue 7, 2008, Pages 1689-1697

  Sharma, Praveen ^b   Kumar, Ashish ^b   Shrama, Brajesh C ^b   Sarin, Shiv K ^a,b  

^a UNIVERSITY OF DELHI   (India)

^b G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; NORADRENALIN; RENIN; TERLIPRESSIN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; LYPRESSIN; VASOCONSTRICTOR AGENT;

ABDOMINAL CRAMP; ADULT; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; FECES; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HEPATORENAL SYNDROME; HUMAN; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT DEPRESSION; TREATMENT RESPONSE; TYPE 1 HEPATORENAL SYNDROME; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; MIDDLE AGED; PILOT STUDY; TREATMENT OUTCOME; URINE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; FEMALE; HEPATORENAL SYNDROME; HUMANS; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; NOREPINEPHRINE; PILOT PROJECTS; RENIN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 50649122545     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01828.x     Document Type: Article

References (25)

1. Gines P,GuevaraM,ArroyoV, et al.Hepatorenal syndrome. Lancet 2003;29;362:1819-27.
2. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome: Pathogenesis and treatment. Gastroenterology 2002;122: 1658-76.
3. Wong F, Blendis L. New challenge of hepatorenal syndrome: Prevention and treatment. Hepatology 2001;34: 1242-51.
4. ArroyoV,Gines P,GerbesAL, et al.De?nition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
5. Arroyo V, Gines P, Jimenez V, et al. Renal dysfunction in cirrhosis. In: McIntyre N, Benemou JP, Rhodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1999;733-61.
6. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
7. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999;10:1833-9.
8. Angeli P, Volpin R, Gerunda G, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
9. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipresin and dopamine. Hepatology 1999;30:870-5.
10. Hadengue A, Gadano A, Moreau R, et al. Bene?cial effects of 2 day administration of terlipressin in patientswith cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
11. Uriz J, Gines P, Cardenas A, et al. Terlipresin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
12. Solanki P, Chawla A, Sarin SK, et al. Bene?cial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6.
13. Anderson WP, Korner PL, Selig SE. Mechanisms involved in the renal response to intravenous and renal artery infusions of noradrenaline in conscious dogs. J Physiol 1981;321:21-30.
14. Bellomo R, Di Giantomasso D. Noradrenaline and the kidney: Friends or foes? Crit Care 2001;5:294-8.
15. Duvoux C, Zanditenas D, Hezodec C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-80.
16. AlessandriaC,OttobrelliA,Debernardi-VenonW, et al.Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505.
17. Sanyal A, Boyer T, Garcia-Tsao G, et al. A prospective, randomized, double blind, placebo controlled trial of terlipressin for type 1 hepatorenal syndrome. Hepatology 2006;44(Suppl):694A.
18. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-47.
19. Bonnard P, Bernard B, Halim C, et al. Effect of terlipressin in hepatorenal syndrome in cirrhotic patients; results of a pilot study. Gastroenterology 1998;114(Suppl 1):A1214.
20. Ortega R,Gines P,Uriz J, et al. Terlipressin therapywith and without albumin for patients with hepatorenal syndrome. Ef?cacy and outcome. Hepatology 2001;36:941-8.
21. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressine) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8
22. Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-42
23. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective study. Gastroenterology 2002;122:923-30.
24. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survial and renal function following liver transplantation inpatients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991;51:428-30.
25. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:287-9.